Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Anitocabtagene Autoleucel in Focus: Insights From the iMMagine-1 Trial at ASH 2024
Saad Z. Usmani, MD, MBA, FACP, discusses how the iMMagine-1 trial, presented at ASH 2024, evaluated the novel chimeric antigen receptor (CAR) T-cell therapy anitocabtagene autoleucel, detailing its study objectives, design, and methodology as well as the promising results that highlight its potential to advance treatment options for multiple myeloma.
EP: 1.Early Intervention in High-Risk Smoldering Myeloma: Results From the AQUILA Study at ASH 2024
EP: 2.Exploring the Frontline Potential of Teclistamab: Insights From MajesTEC-5 at ASH 2024
EP: 3.MRD Outcomes From CEPHEUS at ASH 2024
EP: 4.Transplant-Ineligible Myeloma and MRD Integration: Current Definitions and Future Directions
Now Viewing
EP: 5.Anitocabtagene Autoleucel in Focus: Insights From the iMMagine-1 Trial at ASH 2024
EP: 6.Advancing Multiple Myeloma Care: Insights From ASH 2024 and Beyond
Video content above is prompted by the following:
- Discuss the novel CAR T-cell therapy anitocabtagene autoleucel, as studied in the iMMagine-1 trial and presented at ASH 2024.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
Related Videos
Related Content
ICYMI: Highlights From AMCP Nexus 2024
December 26th 2024Article
Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.
Read More
